Search News Archives
Special Offers and Promotions
Brochures & Literature
Conferences | Events
Synexus focuses on Mild Cognitive Impairment studies
Mild cognitive impairment (MCI) is under the pharma' spotlight as the number of clinical trials currently underway has increased significantly during the past 12 months and the search for treatments that will prevent the progression of MCI to dementia continues. Synexus has teamed up with dementia expert, Dr Roger Bullock, to develop more effective clinical trials for this field.
Dr Bullock has over ten year's clinical trials experience in the field of dementia and is committed to this work as a vital part of the research that will ultimately benefit millions of people worldwide. Dr Christophe Berthoux, Synexus' Chief Executive, is delighted to be working with a leading expert in the field of dementia: "Dr Bullock is widely recognised for his clinical trials work in mild cognitive impairment. We are really excited about teaming up with him to start delivering more effective and faster clinical trials in this area. The financial cost of dementia across the world is set to take off. So not only do we need to address the serious health and quality of life implications of these conditions, we also need to tackle the massive financial burden as a matter of urgency."
Berthoux continues: "Synexus is ideally placed to work in this field, with 26 Dedicated Research Centres across the globe giving us access to a wide and diverse patient population, together with highly experienced clinical investigators with in-depth local knowledge, we can get trials underway fast and deliver consistently robust results."
Synexus has been working with Dr Bullock to ensure its medical staff are appropriately and adequately trained to deliver expertise to clinical trials in this vitally important therapy area, and is currently in talks with several major Pharma's regarding MCI studies.
It is currently estimated that between 10% and 15% of people with MCI will go on to develop dementia. This rises to 50% after five years of diagnosis. There are estimated to be some 35 million people with Alzheimer's Disease worldwide, with around 60% of these in developing countries. Recent studies suggest that the number of people with Alzheimer's Disease in India and China is set to increase by 300% by 2025. Figures like these speak to the importance of developing effective treatments that stall the progression of dementia and ultimately prevent its occurrence. Whilst pharma continues its hunt for the holy grail of dementia, it will need to work closely with organisations like Synexus, to deliver effective studies.
For further information please visit www.synexus.com